A Rich Array of Prostate Cancer Molecular Biomarkers: Opportunities and Challenges
暂无分享,去创建一个
[1] L. Kiemeney,et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. , 2002, Cancer research.
[2] X. Filella,et al. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers , 2016, International journal of molecular sciences.
[3] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[4] S. Srivastava,et al. Ethnicity and ERG frequency in prostate cancer , 2018, Nature Reviews Urology.
[5] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[6] S. Srivastava,et al. Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities , 2018, International journal of molecular sciences.
[7] Martin E. Gleave,et al. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer , 2015, Clinical Cancer Research.
[8] G. Assmann,et al. Isolation of prostate-derived single cells and cell clusters from human peripheral blood. , 1996, Cancer research.
[9] S. Srivastava,et al. Oncogenic activation of ERG: A predominant mechanism in prostate cancer , 2011, Journal of carcinogenesis.
[10] Kazutoshi Fujita,et al. Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology. , 2009, Human pathology.
[11] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[12] David L Rimm,et al. Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer , 2015, Clinical Cancer Research.
[13] A. Hartmann,et al. Expression of GP88 (Progranulin) Protein Is an Independent Prognostic Factor in Prostate Cancer Patients , 2019, Cancers.
[14] A. Haese*,et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: a multicentric European study. , 2013, European urology.
[15] E. Fearon,et al. Cancer progression , 1999, Current Biology.
[16] Ludmila V. Danilova,et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.
[17] W. Catalona,et al. The Prostate Health Index: a new test for the detection of prostate cancer , 2014, Therapeutic advances in urology.
[18] J. Crowley,et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.
[19] David Chia,et al. Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.
[20] Jianbo Li,et al. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. , 2016, Urology.
[21] K. Bibbins-Domingo,et al. The US Preventive Services Task Force 2017 Draft Recommendation Statement on Screening for Prostate Cancer: An Invitation to Review and Comment. , 2017, JAMA.
[22] Y Pawitan,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[23] P. Febbo,et al. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease. , 2018, European urology.
[24] Andrew J. Vickers,et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[25] G. Thalmann,et al. Metastases in Prostate Cancer. , 2019, Cold Spring Harbor perspectives in medicine.
[26] Kassandra I. Alcaraz,et al. Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities , 2016, CA: a cancer journal for clinicians.
[27] F. Feng,et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] V. Moyer,et al. Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.
[29] S. Bentink,et al. A molecular signature of PCA3 and ERG exosomal RNA from non-DRE urine is predictive of initial prostate biopsy result , 2015, Prostate Cancer and Prostatic Disease.
[30] A. Bilancio,et al. Non-Genomic Androgen Action Regulates Proliferative/Migratory Signaling in Stromal Cells , 2014, Front. Endocrinol..
[31] Christopher J Kane,et al. Prostate Cancer, Version 1.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[32] R. Vessella,et al. Evaluation of the Abbott IMx automated immunoassay of prostate-specific antigen. , 1992, Clinical chemistry.
[33] W. Catalona,et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.
[34] Leonard S. Marks,et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. , 2006, Clinical chemistry.
[35] P. Carroll,et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. , 2018, European urology.
[36] Lu Yu,et al. PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. , 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[37] R. Fort,et al. vtRNA2-1/nc886 Produces a Small RNA That Contributes to Its Tumor Suppression Action through the microRNA Pathway in Prostate Cancer , 2020, Non-coding RNA.
[38] D. Chan,et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. , 2004, Urology.
[39] Nan Zhang,et al. A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. , 2015, European urology.
[40] Yair Lotan,et al. Can urinary PCA3 supplement PSA in the early detection of prostate cancer? , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] A. Partin,et al. Risk score predicts high‐grade prostate cancer in DNA‐methylation positive, histopathologically negative biopsies , 2016, The Prostate.
[42] R. Vessella,et al. Detection and characterization of circulating and disseminated prostate cancer cells. , 2007, Frontiers in bioscience : a journal and virtual library.
[43] B. Trock,et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. , 2017, European urology.
[44] Jeonifer M. Garren,et al. Clinical Validation of a Serum Protein Panel (FLNA, FLNB and KRT19) for Diagnosis of Prostate Cancer , 2017, Journal of molecular biomarkers & diagnosis.
[45] Aviv Regev,et al. Whole exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer , 2014, Nature Biotechnology.
[46] T. D. de Reijke,et al. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer , 2015, Clinical Cancer Research.
[47] Anirban P. Mitra,et al. Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy , 2013, PloS one.
[48] Thomas L. Fillmore,et al. Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression , 2020, Cancers.
[49] E. Colás,et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine , 2010, The Prostate.
[50] J. Shimazaki,et al. Progression of prostate cancer to neuroendocrine cell tumor , 2001, International journal of urology : official journal of the Japanese Urological Association.
[51] Wim Van Criekinge,et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. , 2013, The Journal of urology.
[52] E. Colás,et al. A Three‐Gene panel on urine increases PSA specificity in the detection of prostate cancer , 2011, The Prostate.
[53] M. Loda,et al. Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error , 2014, British Journal of Cancer.
[54] Kenneth J. Pienta,et al. Recruitment of Mesenchymal Stem Cells Into Prostate Tumors Promotes Metastasis , 2013, Nature Communications.
[55] B. Trock,et al. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. , 2014, The Journal of urology.
[56] Jeffrey D. Voigt,et al. The Kallikrein Panel for prostate cancer screening: Its economic impact , 2014, The Prostate.
[57] Javed Siddiqui,et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. , 2016, European urology.
[58] W. Ellis,et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[59] Tamara S. Adams,et al. Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis , 2014, Scientific Reports.
[60] Andrew J Vickers,et al. A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[61] Andrew J Vickers,et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden , 2008, BMC medicine.
[62] John T. Wei,et al. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. , 2016, JAMA oncology.
[63] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[64] C. Frezza. The role of mitochondria in the oncogenic signal transduction. , 2014, The international journal of biochemistry & cell biology.
[65] C C Schulman,et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. , 2000, The Journal of urology.
[66] O. Nilsson,et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.
[67] C. Croce,et al. Detection of hematogenous micrometastasis in patients with prostate cancer. , 1992, Cancer research.
[68] J. Ardura,et al. Role of Calcium Signaling in Prostate Cancer Progression: Effects on Cancer Hallmarks and Bone Metastatic Mechanisms , 2020, Cancers.
[69] J Alfred Witjes,et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. , 2003, European urology.
[70] G. Petrovics,et al. Re: Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. , 2018, European urology.
[71] P. Scardino,et al. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. , 2015, European urology.
[72] V. Toscano,et al. Correspondence re: J. B. de Kok et al., DD3, A very sensitive and specific marker to detect prostate tumors. Cancer Res., 62: 2695-2698, 2002. , 2003, Cancer research.
[73] Dan Mercola,et al. Plasma-Derived Exosomal Survivin, a Plausible Biomarker for Early Detection of Prostate Cancer , 2012, PloS one.
[74] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.
[75] J. Schalken,et al. Urinary biomarkers for prostate cancer: a review. , 2013, Asian journal of andrology.
[76] K. Pienta,et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.
[77] L. Amler,et al. PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients , 2015, British Journal of Cancer.
[78] S. Srivastava,et al. Prostate cancer marker panel with single cell sensitivity in urine , 2015, The Prostate.
[79] W. Isaacs,et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.
[80] S. Srivastava,et al. Prostate cancer: Diagnostic performance of the PCA3 urine test , 2011, Nature Reviews Urology.
[81] Dante diTommaso,et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline , 2008, Cancer Causes & Control.
[82] W. Ellis,et al. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. , 2003, Urology.
[83] F. Saad,et al. uPM3, a new molecular urine test for the detection of prostate cancer. , 2004, Urology.
[84] C. Paweletz,et al. Characterization of intracellular prostate-specific antigen from laser capture microdissected benign and malignant prostatic epithelium. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] F. Mostofi,et al. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. , 1995, JAMA.
[86] H. Roca,et al. Immune mediators in the tumor microenvironment of prostate cancer , 2017, Chinese journal of cancer.
[87] L. Klotz,et al. Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay , 2010, Prostate Cancer and Prostatic Diseases.
[88] W. Isaacs,et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.
[89] B. Trock,et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011 , 2013, BJU international.
[90] Xiaohua Li,et al. Diagnostic significance of urinary long non-coding PCA3 RNA in prostate cancer , 2017, Oncotarget.
[91] M. Augustus,et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[92] P. Febbo,et al. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. , 2014, European urology.
[93] T. Rebbeck,et al. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] J. Moul,et al. Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[95] J. Witjes,et al. Molecular PCA3 diagnostics on prostatic fluid , 2007, The Prostate.
[96] F. Hamdy,et al. Changes in circulating microRNA levels associated with prostate cancer , 2012, British Journal of Cancer.
[97] I. Powell,et al. Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. , 2009, Methods in molecular biology.
[98] P. Carroll,et al. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.
[99] Guido Jenster,et al. Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.
[100] T. Rebbeck. Prostate Cancer Disparities by Race and Ethnicity: From Nucleotide to Neighborhood. , 2018, Cold Spring Harbor perspectives in medicine.
[101] P. Carroll,et al. Prostate cancer early detection version 1 , 2014 .
[102] Yuzhuo Wang,et al. Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis. , 2012, Carcinogenesis.
[103] Amy Blase,et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. , 2007, Urology.
[104] Ziding Feng,et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.
[105] Geert Trooskens,et al. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.
[106] J. Schalken,et al. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. , 2003, Urology.
[107] J. Moul,et al. Quantitative expression profile of PSGR in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[108] J. Oesterling,et al. Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.
[109] X. Breakefield,et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer , 2009, British Journal of Cancer.
[110] Martina Tinzl,et al. DD3PCA3 RNA analysis in urine--a new perspective for detecting prostate cancer. , 2004, European urology.
[111] P. Pauwels,et al. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer , 2017, Clinical and Translational Oncology.
[112] Anirban P. Mitra,et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy , 2013, Prostate Cancer and Prostatic Disease.
[113] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[114] John T. Wei,et al. Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer , 2017, JAMA oncology.
[115] T. H. van der Kwast,et al. Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. , 2013, European urology.
[116] R. Bertolla,et al. Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives , 2018, Expert review of proteomics.
[117] John T. Wei,et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. , 2013, Urologic oncology.
[118] Erik Holmberg,et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.
[119] L. Kiemeney,et al. DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .
[120] Matti Nykter,et al. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer. , 2016, JAMA oncology.
[121] Yair Lotan,et al. Systematic review of complications of prostate biopsy. , 2013, European urology.
[122] P. Altevogt,et al. Body fluid derived exosomes as a novel template for clinical diagnostics , 2011, Journal of Translational Medicine.
[123] V. Castronovo,et al. Increased expression of galectin‐1 in carcinoma‐associated stroma predicts poor outcome in prostate carcinoma patients , 2001, The Journal of pathology.
[124] P. Acher,et al. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study , 2020, BMC Medicine.
[125] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[126] G. Murphy,et al. Purification of a human prostate specific antigen. , 1979, Investigative urology.
[127] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[128] Wei Xiong,et al. Role of tumor microenvironment in tumorigenesis , 2017, Journal of Cancer.
[129] M. Brunelli,et al. Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review. , 2016, Clinical genitourinary cancer.
[130] D. Chan,et al. Biomarkers in prostate cancer: what's new? , 2014, Current opinion in oncology.
[131] Sweta Rani,et al. miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression , 2014, The Prostate.
[132] M. Boutros,et al. Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker * , 2017, Molecular & Cellular Proteomics.
[133] T. D. de Reijke,et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. , 2014, European urology.
[134] P. Troncoso,et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. , 2008, The Journal of urology.
[135] Caroline Dive,et al. Molecular analysis of circulating tumour cells—biology and biomarkers , 2014, Nature Reviews Clinical Oncology.
[136] K. Pantel,et al. Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer , 2009, Clinical Cancer Research.
[137] S. Srivastava,et al. Evaluation of the ETS-Related Gene mRNA in Urine for the Detection of Prostate Cancer , 2010, Clinical Cancer Research.
[138] I. Powell. Prostate cancer in the African American: is this a different disease? , 1998, Seminars in urologic oncology.
[139] R. Nawroth,et al. Detection of circulating tumor cells in different stages of prostate cancer , 2013, Journal of Cancer Research and Clinical Oncology.
[140] F. Guimont,et al. Mitochondria, prostate cancer, and biopsy sampling error. , 2013, Discovery medicine.
[141] I. Powell. The precise role of ethnicity and family history on aggressive prostate cancer: a review analysis. , 2011, Archivos espanoles de urologia.
[142] John T. Wei,et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. , 2011, The Journal of urology.
[143] S. Srivastava,et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. , 2008, The Journal of urology.
[144] U. Landegren,et al. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer , 2011, Proceedings of the National Academy of Sciences.
[145] Anirban P. Mitra,et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. , 2013, The Journal of urology.